Minting a new class of polo-like-kinase inhibitors.
Dent
Paul
P
Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA. pdent@vcu.edu
Curiel
David T
DT
Grant
Steven
S
Fisher
Paul B
PB
D000970:Antineoplastic Agents / Q000494:pharmacology*; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D002986:Clinical Trials as Topic; D004258:DNA Polymerase III / Q000378:metabolism; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005656:Fungal Proteins / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D017434:Protein Structure, Tertiary; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors*; D029701:Saccharomyces cerevisiae Proteins / Q000378:metabolism; D013997:Time Factors; D000097869:Polo-Like Kinase 1
D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D004258:DNA Polymerase III; D004791:Enzyme Inhibitors; D005656:Fungal Proteins; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D029701:Saccharomyces cerevisiae Proteins; D000097869:Polo-Like Kinase 1; C491232:POL3 protein, S cerevisiae